Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $CGON
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/7/2025 | Buy | TD Cowen | |
10/24/2024 | $60.00 | Buy | UBS |
9/23/2024 | $66.00 | Outperform | RBC Capital Mkts |
8/28/2024 | $65.00 | Buy | ROTH MKM |
6/28/2024 | $65.00 | Buy | BofA Securities |
2/20/2024 | $75.00 | Overweight | Cantor Fitzgerald |
2/20/2024 | $42.00 | Neutral | Goldman |
2/20/2024 | $55.00 | Overweight | Morgan Stanley |
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
- Durability Results from BOND-003 data will be presented as a late breaker as part of AUA's Practice-changing, Paradigm-shifting Clinical Trials in Urology - - Additional updates from across CG Oncology's clinical trial program, including translational data, planned - IRVINE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced BOND-003 study of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer has been selected as a late breaker as part
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
- Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 Clinical Trial of Cretostimogene Monotherapy in High-Risk BCG-Naïve (Cohort A) and BCG-Exposed (Cohort B) NMIBC - - Late-Breaking Clinical and First Translational Data from BOND-003 Cohort C Presented at the 40th Annual European Association of Urology Congress - - Completed Oversubscribed $238 Million Follow-on Public Equity Offering that Extends Expected Runway into the First Half of 2028 - IRVINE, Calif., March 28, 2025 (GLOBE NEWS
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
– Latest BOND-003 data show 75.5% of patients achieved a complete response at any time –– Median duration of response exceeds 28 months and is ongoing –– No close contact precautions needed post cretostimogene treatment – IRVINE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that 83 out of 110 patients (75.5%) achieved a complete response (CR) at any time in a Phase 3 study of cretostimogene monotherapy for high-risk BCG-unresponsive non-muscle invasive bladder cancer wit
TD Cowen initiated coverage on CG Oncology
TD Cowen initiated coverage of CG Oncology with a rating of Buy
UBS initiated coverage on CG Oncology with a new price target
UBS initiated coverage of CG Oncology with a rating of Buy and set a new price target of $60.00
RBC Capital Mkts initiated coverage on CG Oncology with a new price target
RBC Capital Mkts initiated coverage of CG Oncology with a rating of Outperform and set a new price target of $66.00
Decheng Capital Global Life Sciences Fund Iv, L.P. bought $7,600,000 worth of shares (400,000 units at $19.00) (SEC Form 4) (Amendment)
4/A - CG Oncology, Inc. (0001991792) (Issuer)
Director Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $28,000 worth of shares (1,000 units at $28.00) (SEC Form 4)
4 - CG Oncology, Inc. (0001991792) (Issuer)
Director Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $28,610 worth of shares (1,000 units at $28.61) (SEC Form 4)
4 - CG Oncology, Inc. (0001991792) (Issuer)
Director Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $29,660 worth of shares (1,000 units at $29.66) (SEC Form 4)
4 - CG Oncology, Inc. (0001991792) (Issuer)
SEC Form S-3ASR filed by CG Oncology Inc.
S-3ASR - CG Oncology, Inc. (0001991792) (Filer)
SEC Form 10-K filed by CG Oncology Inc.
10-K - CG Oncology, Inc. (0001991792) (Filer)
CG Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - CG Oncology, Inc. (0001991792) (Filer)
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
- Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 Clinical Trial of Cretostimogene Monotherapy in High-Risk BCG-Naïve (Cohort A) and BCG-Exposed (Cohort B) NMIBC - - Late-Breaking Clinical and First Translational Data from BOND-003 Cohort C Presented at the 40th Annual European Association of Urology Congress - - Completed Oversubscribed $238 Million Follow-on Public Equity Offering that Extends Expected Runway into the First Half of 2028 - IRVINE, Calif., March 28, 2025 (GLOBE NEWS
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
– 74.5% of patients achieved a complete response at any time – – Median duration of response is greater than 27 months and not reached – – Latest data update continued to show favorable safety and tolerability results – – Company hosting virtual investor event with lead investigator at 8 am EST today – IRVINE, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced topline data from the Phase 3 BOND-003 trial in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unr
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 7 am CST on December 5, 2024, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In addition to company executives, this call will feature Mark Tyson, II, M.D., M.P.H., urologic oncologist at Mayo Clinic, and lead investigator in the BOND-003 study. Dr. Tyson is presenti
Amendment: SEC Form SC 13G/A filed by CG Oncology Inc.
SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)
Amendment: SEC Form SC 13G/A filed by CG Oncology Inc.
SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)
SEC Form SC 13G filed by CG Oncology Inc.
SC 13G - CG Oncology, Inc. (0001991792) (Subject)